r/InternalMedicine • u/Born-Implement3739 • 19m ago
Our meta-analysis on Factor XIa inhibitors for secondary stroke prevention has just been published in Brain and Behavior (Wiley)!
Hi everyone!
Excited to share that our systematic review and meta-analysis, “Oral Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack,” has recently been published in Brain and Behavior (Wiley).
We investigated whether oral Factor XIa inhibitors, when added to antiplatelet therapy, could reduce recurrent ischemic stroke without substantially increasing bleeding risk.
🔬 Key Findings:
- 3 randomized controlled trials involving 16,501 participants, with 14,239 included in the primary efficacy analysis.
- 26% relative reduction in recurrent ischemic stroke (RR: 0.74; 95% CI: 0.65–0.84).
- No statistically significant increase in major bleeding (RR: 1.12; 95% CI: 0.87–1.44).
- No significant differences in intracranial hemorrhage or fatal bleeding.
- Trial sequential analysis supported the evidence for recurrent ischemic stroke reduction, while the evidence for major bleeding remained inconclusive.
- Despite antiplatelet therapy, patients with noncardioembolic ischemic stroke remain at risk of recurrent events. Factor XIa inhibition represents a promising therapeutic approach that may improve secondary stroke prevention without substantially compromising safety.
📄 Full article: Oral Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack
I'm grateful to the Research Council of Pakistan (RCOP), Dr. Shariq, Dr. Shahzeb, and Dr. Asad Ali Ahmed Cheema for their guidance and mentorship, and to all my co-authors for their contributions. I'd love to hear the community's thoughts.
Do you think Factor XIa inhibitors could become a meaningful addition to secondary stroke prevention, or do we still need more evidence before considering their broader clinical use?
Looking forward to an interesting discussion!